316 related articles for article (PubMed ID: 33311988)
1. Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient.
Zhang EL; Zhang ZY; Li J; Huang ZY
Onco Targets Ther; 2020; 13():12477-12487. PubMed ID: 33311988
[TBL] [Abstract][Full Text] [Related]
2. Response of Scalp and Skull Metastasis to Anti-PD-1 Antibody Combined with Regorafenib Treatment in a Sorafenib-Resistant Hepatocellular Carcinoma Patient and a Literature Review.
Long X; Zhang L; Wang WQ; Zhang EL; Lv X; Huang ZY
Onco Targets Ther; 2022; 15():703-716. PubMed ID: 35791424
[TBL] [Abstract][Full Text] [Related]
3. Achieving complete remission in metastatic hepatocellular carcinoma with sintilimab plus sorafenib therapy followed by hepatic resection: a case report.
Cui K; Li Z; Zhong J; Shi X; Zhao L; Li H; Ma Y
Front Oncol; 2024; 14():1355798. PubMed ID: 38380371
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China.
Ren SH; Cui ZL; Lang MR; Li Q; Zhang W; Fang F; Wu Q; Cui YL; Li HK; Chen P; Zhang Y; Song T
J Gastrointest Oncol; 2022 Jun; 13(3):1266-1277. PubMed ID: 35837206
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.
Zhang Y; Zhang F; Zhao L; Fu X; Shang Y; Gao Q
BMC Gastroenterol; 2021 Oct; 21(1):399. PubMed ID: 34688262
[TBL] [Abstract][Full Text] [Related]
6. Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation.
Lee SK; Jang JW; Nam H; Sung PS; Bae SH; Choi JY; Yoon SK
J Liver Cancer; 2020 Mar; 20(1):84-89. PubMed ID: 37383051
[TBL] [Abstract][Full Text] [Related]
7. Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib.
Wang H; Xiao W; Han Y; Cao S; Zhang Z; Chen G; Hu Y; Jin L
J Gastrointest Oncol; 2022 Aug; 13(4):1907-1914. PubMed ID: 36092351
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance.
Zou X; Xu Q; You R; Yin G
J Hepatocell Carcinoma; 2023; 10():267-279. PubMed ID: 36815093
[TBL] [Abstract][Full Text] [Related]
9. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Wang HW; Chuang PH; Su WP; Kao JT; Hsu WF; Lin CC; Huang GT; Lin JT; Lai HC; Peng CY
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359658
[TBL] [Abstract][Full Text] [Related]
10. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.
Sun H; Xing C; Jiang S; Yu K; Dai S; Kong H; Jin Y; Shan Y; Yang W; Wang Z; Xiao J; Wang H; Wang W; Li Z; Shi K
Front Immunol; 2022; 13():963031. PubMed ID: 36059488
[TBL] [Abstract][Full Text] [Related]
11. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
Ogasawara S; Ooka Y; Itokawa N; Inoue M; Okabe S; Seki A; Haga Y; Obu M; Atsukawa M; Itobayashi E; Mizumoto H; Sugiura N; Azemoto R; Kanayama K; Kanzaki H; Maruta S; Maeda T; Kusakabe Y; Yokoyama M; Kobayashi K; Kiyono S; Nakamura M; Saito T; Suzuki E; Nakamoto S; Yasui S; Tawada A; Chiba T; Arai M; Kanda T; Maruyama H; Kato N
Invest New Drugs; 2020 Feb; 38(1):172-180. PubMed ID: 31172442
[TBL] [Abstract][Full Text] [Related]
12. Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma.
Joerger M; Güller U; Bastian S; Driessen C; von Moos R
J Gastrointest Oncol; 2019 Apr; 10(2):373-378. PubMed ID: 31032109
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report.
Wan Y; Zhu H
Front Oncol; 2023; 13():1256137. PubMed ID: 37881484
[TBL] [Abstract][Full Text] [Related]
14. PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib.
Xu Y; Fu S; Shang K; Zeng J; Mao Y
Front Oncol; 2022; 12():958869. PubMed ID: 36176403
[TBL] [Abstract][Full Text] [Related]
15. [Sustained Complete Response of Hepatocellular Carcinoma with Multiple Intrahepatic Metastases following the Discontinuation of Sorafenib].
Takeda Y; Ohmura Y; Katsura Y; Sakamoto T; Nose Y; Mori R; Inatome J; Kawai K; Naito A; Murakami K; Kagawa Y; Masuzawa T; Takeno A; Egawa C; Murata K
Gan To Kagaku Ryoho; 2019 Mar; 46(3):532-536. PubMed ID: 30914605
[TBL] [Abstract][Full Text] [Related]
16. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
Yoo C; Park JW; Kim YJ; Kim DY; Yu SJ; Lim TS; Lee SJ; Ryoo BY; Lim HY
Invest New Drugs; 2019 Jun; 37(3):567-572. PubMed ID: 30523474
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.
Jindal A; Thadi A; Shailubhai K
J Clin Exp Hepatol; 2019; 9(2):221-232. PubMed ID: 31024205
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study.
Huang J; Guo Y; Huang W; Hong X; Quan Y; Lin L; Zhou J; Liang L; Zhang Y; Zhou J; Cai M; Zhu K
J Hepatocell Carcinoma; 2022; 9():157-170. PubMed ID: 35300208
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):611-617. PubMed ID: 29040994
[TBL] [Abstract][Full Text] [Related]
20. Locoregional treatment improves overall survival for liver cancer during second-line regorafenib or immune checkpoint inhibitor.
Lin PT; Hsu YC; Kao YT; Teng W; Hsieh YC; Chen WT; Su CW; Wang CT; Chai PM; Lin CC; Lin CY; Lin SM
Am J Cancer Res; 2024; 14(3):1306-1315. PubMed ID: 38590407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]